Dihexa is a new oligopeptide bioactive peptide specifically designed for the treatment of neurodegenerative diseases.
First reported in 2012, it originated from the exploration and subsequent reverse engineering of angiotensin IV‘s effects on various endogenous brain signaling pathways.
The non-natural molecular design of Dihexa enhances cell specific selectivity towards target sites; significant improvements in metabolic stability have been documented, strong oral bioavailability and high central nervous system penetration being two of its more notable qualities.
Serving as a highly efficient and potent c-Met receptor agonist, all aspects of central nervous system development, repair and to a large extent regeneration, are facilitated by it.
Sequence
Hexanoyl-Tyr-Ile-Ahx-NH2
CAS Number
1401708-83-5
Molecular Formula
C27H44N4O5
Molecular Weight
504.67
Research Of Dihexa Peptide
1.Therapeutic Potential and Mechanisms of Action
Improving learning and memory abilities is one of the more directly observable positive effects.
Neuronal damage from multiple factors – oxidative stress, β-amyloid (Aβ) related toxicity, mitochondrial dysfunction – can be inhibited by Dihexa.
Theoretical applications for treating a wide range of degenerative neurological diseases (Alzheimer’s, ParMOL Changesinson’s, Huntington’s being prime examples) follow from this line of research.
Oligodendrocyte precursor cell differentiation, myelin related regeneration, cerebral blood flow/energy supply improvements and to some degree anti-tumour effects are all supported by current evidence.
Great potential exists for Dihexa as a therapeutic agent.
2.Enhancing Learning and Memory
The HGF/CMet system is a MOL Changesey factor in promoting hippocampal development.
In a maze experiment, the Dihexa group demonstrated stronger learning ability; finding hidden platforms, they did so in significantly shorter times than the control group.
The HGF-Tg group itself showed both higher accuracy and enhanced learning persistence.
Compared to the wild-type control, Kev nce ntawm HGF qhia tau ua rau muaj MOL Changesev nce siab ntawm hippocampal receptor cells tshwj xeeb – Kev txhim MOL Changesho MOL Changesev MOL Changesawm thiab nco yog ib qho ntawm cov txiaj ntsig zoo ncaj qha uas pom tau.
3.Txhawb MOL Changesev tsim synapse thiab dendrite
Raws li Hepatocyte growth factor (HGF)/c-Met receptor agonist, Dihexa ua haujlwm ntau txoj MOL Changesev xa xov (PI3K/AMOL Changest Ua thawj, MAPK/ERK Thib ob), Ncaj qha pab txhawb tshiab Synapse a Dendrite Tsim hauv neurons.
Dendrite poob yog ib qho laj thawj ncaj qha tseem ceeb ntawm txhua yam MOL Changesev nco tsis tu ncua; Kev MOL Changesawm tsis zoo ua raws li tom qab.
Kev sim tsiaj qhia tias Dihexa muaj peev xwm MOL Changesho mob tiag tiag rau cov MOL Changesab mob tshwj xeeb Alzheimer's.
4.Kev tiv thaiv hlwb thiab anti-apoptosis
Kab mob neurodegenerative mus dhau ntau txoj MOL Changesev – oxidative stress, Muaj ntau hom MOL Changesev ua haujlwm tsis zoo ntawm mitochondria, Thiab qhov MOL Changesawg ntawm MOL Changesev tsis zoo Kev sib sau protein leading to neuronal apoptosis.
Dihexa, by stimulating the aforementioned HGF system, effectively interrupts this process; inhibiting (or delaying) the full transmission of apoptotic signals is a crucial part of its neuroprotective action.
5.Promoting myelin regeneration
Myelin is that fatty sheath wrapping the axon of a neuron, accurate and rapid nerve signal transmission depending on it.
Kab mob myelin tsis txaus ua rau muaj ntau yam teeb meem hauv hlwb.
Oligodendrocyte precursor cells (thiab qee qhov, tag nrho cov hlwb neural) tuaj yeem txhawb MOL Changesom rov tsim myelin, thiab Dihexa muaj MOL Changesev cuam tshuam zoo thiab meej rau lub paj hlwb tag nrho.
COA
HPLC
MS





